Lv6
2750 积分 2022-01-20 加入
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
27天前
已完结
Decision analysis of pelvic lymph node dissection during radical prostatectomy
27天前
已关闭
Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer
27天前
已关闭
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
1个月前
已完结
Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
1个月前
已完结
Resisting RECIST: PSMA PET and Regulatory Change in Prostate Cancer
1个月前
已关闭
Decision analysis of pelvic lymph node dissection during radical prostatectomy
1个月前
已关闭
The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer
1个月前
已完结
External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-specific Membrane Antigen Positron Emission Tomography-based PRIMARY Score
1个月前
已完结
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
1个月前
已完结
皖公网安备34019202002308
